Table 2.
Treatment outcomes for patients with UR-LAPC who underwent gemcitabine plus nab-paclitaxel as first-line chemotherapy.
| All | CRT Group | CTx Group | p-Value | |
|---|---|---|---|---|
| (n = 45) | (n = 25) | (n = 20) | ||
| Best response | ||||
| CR | 1 | 1 | 0 | |
| PR | 17 | 11 | 6 | |
| SD | 24 | 13 | 11 | |
| PD | 2 | 0 | 2 | |
| NE | 1 | 0 | 1 | |
| Best overall response rate (%) | 40 | 48 | 30 | 0.359 † |
| Disease control rate (%) | 93.3 | 100 | 85 | 0.080 † |
| Progression-free survival time (months § [95% CI]) |
16.0 (12.3–20.9) |
18.5 (15.0–22.7) |
7.6 (5.3–21.4) |
0.036 ‡ |
| Duration of local response (months, § [95% CI]) |
22.0 (18.3–25.4) |
24.2 (20.3–30.4) |
10.3 (5.3–25.2) |
0.005 ‡ |
| Overall survival time (months, § [95% CI]) |
25.5 (18.8–28.5) | 29.2 (25.4–35.4) | 17.4 (11.2–25.9) | <0.001 ‡ |
CI, confidence interval; CR, complete response; NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease; UR-LAPC, unresectable locally advanced pancreatic cancer. The CRT group (n = 25) included patients who underwent chemoradiotherapy following induction chemotherapy with gemcitabine plus nab-paclitaxel. The CTx group (n = 20) included patients who underwent systemic chemotherapy alone. † Fisher’s exact test, ‡ Log-rank test, § Median Statistical significance at p < 0.05.